| pubmed-article:15370258 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15370258 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15370258 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:15370258 | lifeskim:mentions | umls-concept:C1749467 | lld:lifeskim |
| pubmed-article:15370258 | lifeskim:mentions | umls-concept:C0376545 | lld:lifeskim |
| pubmed-article:15370258 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:15370258 | lifeskim:mentions | umls-concept:C1366561 | lld:lifeskim |
| pubmed-article:15370258 | lifeskim:mentions | umls-concept:C0175630 | lld:lifeskim |
| pubmed-article:15370258 | lifeskim:mentions | umls-concept:C0376315 | lld:lifeskim |
| pubmed-article:15370258 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:15370258 | pubmed:dateCreated | 2004-9-16 | lld:pubmed |
| pubmed-article:15370258 | pubmed:abstractText | The release of soluble forms of CD80 provides a potentially powerful mechanism for the modulation of anti-tumor responses. In this report we investigated whether a soluble form of CD80 (sCD80) circulates in vivo and whether levels are altered in patients with hematological malignancies. Circulating sCD80 was detected by ELISA in all normal donor (0.024-0.318 ng/ml) and patient (0.02-3.75 ng/ml) blood analyzed. The majority of acute myeloid leukemia (13/17) and multiple myeloma (11/12) patients had normal sCD80 levels. Significantly elevated levels were detected in chronic lymphocytic leukemia (CLL, P = 0.0001) and mantle cell lymphoma (MCL, P = 0.0002) patients. MCL patients had the highest levels with 8/9 having levels > 0.318 ng/ml. Increased sCD80 levels in CLL were significantly associated with poor prognosis markers such as low platelet (P = 0.01) and hemoglobin (P = 0.002) levels, elevated WBC counts (P = 0.03) and expression of CD38 (P = 0.048). The immunoreactivity of the sCD80 in both normal and patient plasma was inhibited by the presence of CTLA-4-Ig, suggesting sCD80 is functional. Comparison of sCD80 and soluble CD86 levels demonstrated that these molecules were independently elevated in 39% of patients. The finding that a proportion of CLL and the majority of MCL patients contain elevated levels of sCD80 and the demonstration that sCD80 can interact with CTLA-4-Ig suggests a potential role for sCD80 in modulating anti-tumor responses during the malignant process. | lld:pubmed |
| pubmed-article:15370258 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15370258 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15370258 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15370258 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15370258 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15370258 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:15370258 | pubmed:author | pubmed-author:McKenzieJ LJL | lld:pubmed |
| pubmed-article:15370258 | pubmed:author | pubmed-author:BonoFF | lld:pubmed |
| pubmed-article:15370258 | pubmed:author | pubmed-author:StarlingG CGC | lld:pubmed |
| pubmed-article:15370258 | pubmed:author | pubmed-author:PattonW NWN | lld:pubmed |
| pubmed-article:15370258 | pubmed:author | pubmed-author:HockB DBD | lld:pubmed |
| pubmed-article:15370258 | pubmed:author | pubmed-author:SalkLL | lld:pubmed |
| pubmed-article:15370258 | pubmed:author | pubmed-author:McArthurL TLT | lld:pubmed |
| pubmed-article:15370258 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15370258 | pubmed:volume | 45 | lld:pubmed |
| pubmed-article:15370258 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15370258 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15370258 | pubmed:pagination | 2111-8 | lld:pubmed |
| pubmed-article:15370258 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:meshHeading | pubmed-meshheading:15370258... | lld:pubmed |
| pubmed-article:15370258 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15370258 | pubmed:articleTitle | Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. | lld:pubmed |
| pubmed-article:15370258 | pubmed:affiliation | Haematology Research Group, Christchurch Hospital, New Zealand. barry.hock@chmeds.ac.nz | lld:pubmed |
| pubmed-article:15370258 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15370258 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15370258 | lld:pubmed |
